This full turnkey mRNA vaccine production facility delivers one-stop integrated solution, covering cleanroom construction, HVAC purified air system, WFI & pure steam utility station, complete process equipment layout installation, automation integration, validation support and regulatory submission consulting, fully tailored for cGMP-compliant commercial mRNA vaccine industrial production.
The complete production workflow covers plasmid DNA fermentation & purification, linearization template preparation, in vitro transcription (IVT) mRNA synthesis, mRNA downstream purification, LNP encapsulation & formulation, sterile aseptic fill-finish, finished product ultra-low temperature cold storage and dedicated QC quality testing laboratory modules. Modular zoning strictly separates high-biohazard plasmid processing area, RNA synthesis zone, LNP formulation workshop and aseptic filling suite, with independent pressure cascade control, explosive-proof ventilation and dedicated biowaste treatment systems to address ethanol and organic solvent safety risks unique to mRNA manufacturing.
Core process equipment adopts flexible dual technical routes of single-use bioprocess skids and sanitary stainless steel fixed systems. Low-shear inline mixing technology protects mRNA integrity and LNP nanoparticle stability; automated TFF purification, inline buffer preparation and fully closed fluid pipelines eliminate open operation contamination risks. Unified central PLC control system realizes full recipe management, real-time parameter monitoring, batch data logging, audit trail and electronic signature functions, fully complying with FDA, EMA, WHO nucleic acid vaccine guidelines and 21 CFR Part 11 data integrity requirements.
We provide full FAT/SAT on-site commissioning, IQ/OQ/PQ validation document package, staff operation training and long-term after-sales technical support. The facility supports seamless capacity scaling from clinical trial pilot batches to hundreds of millions of annual vaccine doses, compatible with multi-strain rapid product switchover for variant vaccine upgrades. This turnkey project shortens factory construction and validation cycle drastically, lowers investment risks, and helps clients rapidly build independent domestic mRNA vaccine industrial capacity and complete global regulatory registration and commercial launch.
